Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination
Tarek Taifour, Adéline Massé, Yu Gu, Virginie Sanguin-Gendreau, Dongmei Zuo, Bin Xiao, Emilie Solymoss, Yunyun Shen, Hailey Proud, Sherif Samer Attalla, Vasilios Papavasiliou, Nancy U. Lin, Melissa E. Hughes, Kalie Smith, Chun Geun Lee, Suchitra Kamle, Josie Ursini-Siegel, Jack A. Elias, Peter M. Siegel, Rinath Jeselsohn, William J. Muller
Tarek Taifour, Adéline Massé, Yu Gu, Virginie Sanguin-Gendreau, Dongmei Zuo, Bin Xiao, Emilie Solymoss, Yunyun Shen, Hailey Proud, Sherif Samer Attalla, Vasilios Papavasiliou, Nancy U. Lin, Melissa E. Hughes, Kalie Smith, Chun Geun Lee, Suchitra Kamle, Josie Ursini-Siegel, Jack A. Elias, Peter M. Siegel, Rinath Jeselsohn, William J. Muller
View: Text | PDF
Research Article Immunology Oncology

The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination

  • Text
  • PDF
Abstract

Immunosuppression and metastasis are critical hallmarks of breast cancer, often linked to poor patient outcomes. The secreted cytokine chitinase-3–like 1 (CHI3L1) is frequently overexpressed in breast cancer samples and promotes an immunosuppressed tumor microenvironment. Notably, CHI3L1 expression is elevated in metastatic patient samples when compared with the matched primary breast tumor. To investigate its role in breast cancer metastasis, we generated an inducible genetically engineered mouse model that overexpresses CHI3L1 in the mammary epithelium. Ectopic expression of CHI3L1 in the polyomavirus middle T (PyMT) mouse model of breast cancer suppressed antitumor immune responses, accelerated mammary tumor onset, and enhanced lung metastasis. Mechanistically, elevated CHI3L1 expression in the mammary epithelium enhanced neutrophil recruitment, which subsequently degraded the extracellular matrix and increased the number of circulating tumor cells. These findings reveal a key mechanism driving metastatic dissemination and argue that therapeutically targeting Chi3l1 could enhance antitumor immunity and suppress metastasis.

Authors

Tarek Taifour, Adéline Massé, Yu Gu, Virginie Sanguin-Gendreau, Dongmei Zuo, Bin Xiao, Emilie Solymoss, Yunyun Shen, Hailey Proud, Sherif Samer Attalla, Vasilios Papavasiliou, Nancy U. Lin, Melissa E. Hughes, Kalie Smith, Chun Geun Lee, Suchitra Kamle, Josie Ursini-Siegel, Jack A. Elias, Peter M. Siegel, Rinath Jeselsohn, William J. Muller

×

Figure 1

Chi3l1 OE rescues mammary tumor onset in Stat3-deficient MIC mice.

Options: View larger image (or click on image) Download as PowerPoint
Chi3l1 OE rescues mammary tumor onset in Stat3-deficient MIC mice.
(A) S...
(A) Schematic representation of the MTB MIC Stat3–/– Chi3l1 OE GEMM used in this study. Created in BioRender (Muller W, 2026, https://BioRender.com/avc83im). (B) Representative hematoxylin and eosin (H&E) staining of WT, Chi3l1 OE, Stat3–/–, and Stat3–/– Chi3l1 OE MIC mammary glands at 2 weeks after induction. (C) Quantification of hyperplastic area in WT (n = 12), Chi3l1 OE (n = 5), Stat3–/– (n = 11), and Stat3–/– Chi3l1 OE (n = 12) MIC mammary glands at 2 weeks after induction. Represented as percentage of total mammary gland area. (D) Quantification of hyperplastic area in WT (n = 11), Chi3l1 OE (n = 7), Stat3–/– (n = 11), and Stat3–/– Chi3l1 OE (n = 11) MIC mammary glands at 6 weeks after induction. Represented as percentage of total mammary gland area. (E) Representative H&E staining of WT, Chi3l1 OE, Stat3–/–, and Stat3–/– Chi3l1 OE MIC mammary glands at 6 weeks after induction. (F) Mammary tumor onset in WT (n = 29), Chi3l1 OE (n = 20), Stat3–/– (n = 40), and Stat3–/– Chi3l1 OE (n = 28) MIC mice, tracked by weekly physical palpation. Analysis by log-rank test. (G) Summary of mammary tumor onset and penetrance in WT, Chi3l1 OE, Stat3–/–, and Stat3–/– Chi3l1 OE MIC mice. *P < 0.05, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA with Tukey’s post hoc test. Scale bars: 500 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts